☆ 4.3 Letter

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

HEMASPHERE (2022)

Journal

HEMASPHERE

Volume 6, Issue 11, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1097/HS9.0000000000000789

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Hematology

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-Garcia, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthoj, Jaap van Doesum, Yavuz M. Bilgin, Alberto Lopez-Garcia, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerova, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valkovic, Iker Falces-Romero, Sonia Martin-Perez, Moraima Jimenez, Julio Davila-Valls, Martin Schonlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, Laszlo Imre Pinczes, Caterina Buquicchio, Klara Piukovics, Irati Ormazabal-Velez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Mendez, Jose-Angel Hernandez-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciume, Cristina de Ramon, Nick de Jonge, Josip Batinic, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemi Fernandez, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdenek Racil, Marcio Nucci, Milos Mladenovic, Raphael Lievin, Michaela Hanakova, Stefanie Grafe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adzic-Vukicevic, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely

Summary: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-SARS-CoV-2 vaccination. This study found a relatively low mortality rate among patients with breakthrough COVID-19, with the Omicron variant being the predominant strain. Patients receiving monoclonal antibody treatment had a lower mortality rate.

BLOOD (2022)

Add to Collection

Review Hematology

COVID-19 in patients with hematologic malignancy

Petra Langerbeins, Michael Hallek

Summary: COVID-19 exhibits symptomatic heterogeneity and has a significant impact on the immune response of patients with hematologic malignancy. Vaccination against SARS-CoV-2 is important, but the immune response in these patients may be impaired. Antiviral drugs and monoclonal antibodies are available for prevention and treatment of COVID-19, but their efficacy may decrease against new variants.

BLOOD (2022)

Add to Collection

Article Oncology

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose

Idan Cohen, Salvatore Campisi-Pfinto, Orit Rozenberg, Raul Colodner, Gil Bar-Sela

Summary: Since January 2022, high-risk populations in Israel have been advised to receive a fourth dose of the BNT162b2 vaccine for protection against SARS-CoV-2. This study monitored the vaccine-induced immunity among oncology patients undergoing anti-cancer therapy before and after the fourth dose of BNT162b2. The results showed that antibody levels were higher in patients who had breakthrough infections or received the fourth dose, compared to the control group.

ONCOLOGIST (2023)

Add to Collection

Article Immunology

SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?

Cristina Stasi, Barbara Meoni, Fabio Voller, Caterina Silvestri

Summary: The SARS-CoV-2 pandemic has led to extensive vaccine research, with numerous vaccines in various stages of development. Vaccines have proven to be safe and effective in reducing the spread of the virus and its variants, as well as the severity of COVID-19. Studies have shown that a third dose can provide high levels of protection against symptomatic infection and reinfection by variants.

VACCINES (2022)

Add to Collection

Article Immunology

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373

Katia Alves, Joyce S. Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Kathy Smith, Alex Marcheschi, Susan Pfeiffer, Heather McFall, Gale Smith, Gregory M. Glenn, Filip Dubovsky, Raburn M. Mallory

Summary: The emergence of SARS-CoV-2 variants has reduced vaccine efficacy. A study found that a fourth dose of NVX-CoV2373 increased cross-reactive antibody response to variants, without increasing adverse reactions. Updating the vaccine composition may not be necessary at the moment.

VACCINE (2023)

Add to Collection

Article Medicine, General & Internal

Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria

Alena Chalupka, Lukas Richter, Ali Chakeri, Ziad El-Khatib, Verena Theiler-Schwetz, Christian Trummer, Robert Krause, Peter Willeit, Bernhard Benka, John P. A. Ioannidis, Stefan Pilz

Summary: This study aimed to evaluate the risk of COVID-19 deaths and SARS-CoV-2 infections associated with a fourth vaccine dose in individuals with prior SARS-CoV-2 infections. The study findings showed that a fourth vaccine dose was not associated with an increased risk of COVID-19 deaths but temporarily reduced the risk of SARS-CoV-2 infections. However, this effect reversed over time in longer follow-up.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2023)

Add to Collection

Article Virology

Antibody response following the fourth SARS-CoV-2 vaccine dose during the Omicron wave in Brazil

Maria Francilene Souza Silva, Fatima de Cassia Evangelista de Oliveira, Ana Carolina M. Dinelly Pinto, Maria Claudia dos S. Luciano, Max Moreira Lizano Garcia, Fernanda Montenegro de C. Araujo, Marcela H. Gambim Fonseca

Summary: We investigated the impact of the fourth dose of ChAdOx1 nCoV-19 in the humoral immune response to SARS-CoV-2 during a 9-month follow-up period in Brazil, where Omicron was the predominant variant. The study found that the additional antibody response to the viral spike protein after the fourth dose was smaller than after the third dose, while the levels of IgG for the nucleocapsid protein increased. There was no significant decline in IgG levels after the fourth dose, indicating a sustained humoral response to both the spike and nucleocapsid proteins.

JOURNAL OF MEDICAL VIROLOGY (2023)

Add to Collection

Article Rheumatology

Fourth dose of BNT162b2 vaccine for patients with autoimmune rheumatic diseases in a nationwide setting

Amir Bieber, Shay Brikman, Lena Novack, Ran Abuhasira, Abdallah Fawaz, Mahmoud Abu-Shakra, Lior Zeller, Eduard Ling, Reuven Mader, Iftach Sagy

Summary: This study aimed to evaluate the need for a fourth COVID-19 vaccination in patients with autoimmune rheumatic diseases. The analysis found that patients who received the fourth dose of the vaccine had a lower risk of COVID-19 infection, hospitalization, and death compared to those who had not been infected with COVID-19 and received three doses of the vaccine.

RHEUMATOLOGY (2023)

Add to Collection

Article Urology & Nephrology

A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis

Maxime Espi, Xavier Charmetant, Thomas Barba, Cyrille Mathieu, Caroline Pelletier, Laetitia Koppe, Elodie Chalencon, Emilie Kalbacher, Virginie Mathias, Anne Ovize, Emmanuelle Cart-Tanneur, Christine Bouz, Laurence Pellegrina, Emmanuel Morelon, Laurent Juillard, Denis Fouque, Cecile Couchoud, Olivier Thaunat

Summary: The level of protection provided by two doses of COVID-19 mRNA vaccines in patients receiving maintenance hemodialysis (MHD) is uncertain. This study found that vaccination significantly reduced the incidence and severity of COVID-19, but 11% of patients infected after two doses still died. Lack of protection in SARS-CoV-2-naive patients could be due to defective T-cell response and failure to generate sufficient neutralizing antibodies after vaccination. Administering a third dose of vaccine improved protection in low/no responders. High responders did not show an increase in antibodies after the third dose but experienced more side effects. The antibody and T-cell response after two doses can guide personalized administration of the third dose in MHD patients.

KIDNEY INTERNATIONAL (2022)

Add to Collection

Article Immunology

Factors Associated with Not Receiving a Booster Dose of COVID-19 Vaccine in Peru

Guido Bendezu-Quispe, Brenda Caira-Chuquineyra, Daniel Fernandez-Guzman, Diego Urrunaga-Pastor, Percy Herrera-Anazco, Vicente A. Benites-Zapata

Summary: Sociodemographic characteristics and a history of having had COVID-19 were associated with the probability of not having received the booster dose for COVID-19 in the Peruvian population.

VACCINES (2022)

Add to Collection

Article Virology

A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice

Bing Zhou, Shuo Song, Huimin Guo, Xinrong Zhou, Qing Fan, Weilong Liu, Lin Cheng, Xiangyang Ge, Bin Ju, Zheng Zhang

Summary: This study demonstrates that using the Omicron BA.1 RBD as a fourth dose of vaccine can induce potent Omicron-specific neutralizing antibodies and exhibit broadly neutralizing activities against SARS-CoV-2 variants when used in sequential immunization.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Oncology

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

Josef Singer, Nguyen-Son Le, Daniel Mattes, Valerie Klamminger, Klaus Hackner, Nicole Kolinsky, Michaela Scherb, Peter Errhalt, Gudrun Kreye, Martin Pecherstorfer, Sonia Vallet, Klaus Podar

Summary: Vaccination is the primary public health strategy to combat the COVID-19 pandemic, with solid tumor and hematologic patients being at higher risk of severe complications. Data on immune responses to COVID-19 vaccines in these patients are scarce. Complete vaccination is a valuable predictor for high anti-SARS-CoV-2 antibody responses in these vulnerable patient groups.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities

Khitam Muhsen, Nimrod Maimon, Amiel Yaron Mizrahi, Boris Boltyansky, Omri Bodenheimer, Zafrira Hillel Diamant, Lea Gaon, Dani Cohen, Ron Dagan

Summary: The results of this cohort study suggest that receipt of a fourth BNT162b2 dose provided high protection against COVID-19 hospitalizations and deaths among LTCF residents during a substantial Omicron variant surge, but the protection against infection was modest.

JAMA INTERNAL MEDICINE (2022)

Add to Collection

Article Medicine, Research & Experimental

One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19

Riccardo Levi, Elena Azzolini, Chiara Pozzi, Leonardo Ubaldi, Michele Lagioia, Alberto Mantovani, Maria Rescigno

Summary: A study showed that individuals with prior exposure to SARS-CoV-2 had a significant increase in antibody response within 5 to 18 days after receiving the Pfizer/BioNTech vaccine. Symptomatic individuals reached a high titer of antibodies with just one dose, suggesting that a second dose may not be necessary.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Immunology

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5

Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratchadawan Aeemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thanunrat Thongmee, Donchida Srimuan, Thaksaporn Thatsanathorn, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan

Summary: The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 μg BNT162b2 and 50 μg mRNA-1273 vaccines. A total of 292 healthy adults received BNT162b2 or mRNA-1273 and the reactogenicity was mild to moderate and well tolerated. The study found that both BNT162b2 and mRNA-1273 vaccines can be used as a fourth booster dose for individuals who were previously immunized with any prior three-dose mix-and-match COVID-19 vaccine regimens.

VACCINES (2023)

Add to Collection

Article Hematology

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

Francesco Marchesi, Jon Salmanton-Garcia, Ziad Emarah, Klara Piukovics, Marcio Nucci, Alberto Lopez-Garcia, Zdenek Racil, Francesca Farina, Marina Popova, Sofia Zompi, Ernesta Audisio, Marie-Pierre Ledoux, Luisa Verga, Barbora Weinbergerova, Tomas Szotkovski, Maria Gomes Da Silva, Nicola Fracchiolla, Nick De Jonge, Graham Collins, Monia Marchetti, Gabriele Magliano, Carolina Garcfa-Vidal, Monika M. Biernat, Jaap Van Doesum, Marina Machado, Fatih Demirkan, Murtadha Al-Khabori, Pavel Zak, Benjamfn Vfsek, Igor Stoma, Gustavo-Adolfo Mendez, Johan Maertens, Nina Khanna, Ildefonso Espigado, Giulia Dragonetti, Luana Fianchi, Maria Ilaria Del Principe, Alba Cabirta, Irati Ormazabal-Velez, Ozren Jaksic, Caterina Buquicchio, Valentina Bonuomo, Josip Batinic, Ali S. Omrani, Sylvain Lamure, Olimpia Finizio, Noemf Fernandez, Iker Falces-Romero, Ola Blennow, Rui Bergantim, Natasha Ali, Sein Win, Jens Van Praet, Maria Chiara Tisi, Ayten Shirinova, Martin Schoenlein, Juergen Prattes, Monica Piedimonte, Verena Petzer, Milan Navratil, Austin Kulasekararaj, Pavel Jindra, Jiff Sramek, Andreas Glenthoj, Rita Fazzi, Cristina De Ramon-Sanchez, Chiara Cattaneo, Maria Calbacho, Nathan C. Bahr, Shaimaa El-Ashwah, Raul Cordoba, Michaela Hanakova, Giovanni Paolo Maria Zambrotta, Giovanni Zambrotta, Mariarita Sciume, Stephen Booth, Raquel Nunes Rodrigues, Maria Vittoria Sacchi, Nicole Garcia-Pouton, Juan-Alberto Martin-Gonzalez, Sofya Khostelidi, Stefanie Graefe, Laman Rahimli, Emanuele Ammatuna, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Oliver A. Cornely, Livio Pagano

Summary: Patients with acute myeloid leukemia (AML) who are diagnosed with COVID-19 are at high risk of death. The management of AML patients with COVID-19 has not been established. In our study, a significant number of AML patients receiving or having received AML treatment had severe or critical COVID-19. Chemotherapy was modified or discontinued in a substantial portion of patients. The mortality rate was high, and survival was better when AML treatment could be delayed.

HAEMATOLOGICA (2023)

Add to Collection

Editorial Material Allergy

SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report

M. Criscuolo, J. Salmanton-Garcia, N. Fracchiolla, G. Dragonetti, N. Khanna, B. Weinbergerova, M. Schoenlein, M. Machado, J. Labrador, M. Kolditz, F. Itri, M. Gomes Da Silva, V Bonuomo, M. Sciume, R. Nunes Rodrigues, S. Graefe, F. Marchesi, O. A. Cornely, L. Pagano

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2023)

Add to Collection

Article Hematology

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis

Silvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, Sara Pezzatti, Angelo Belotti, Francesca Fazio, Roberto Mina, Magda Marcatti, Anna Cafro, Renato Zambello, Laura Paris, Gregorio Barila, Cecilia Olivares, Alessandra Pompa, Rita Mazza, Francesca Farina, Martina Soldarini, Pietro Benvenuti, Giuseppina Pagani, Michele Palumbo, Valeria Masoni, Virginia Valeria Ferretti, Catherine Klersy, Luca Arcaini, Maria Teresa Petrucci

Summary: Lenalidomide and dexamethasone-based triplets, especially carfilzomib-Rd (KRd) and daratumumab-Rd (DaraRd), are commonly used in lenalidomide-sensitive multiple myeloma (MM) patients in first relapse. A retrospective analysis comparing DaraRd and KRd showed that DaraRd had similar overall-response rate (ORR) and very good partial response (VGPR) rate, but longer median progression-free survival (PFS) and lower non-hematological toxicity rate. However, there were some performance gaps compared to randomized clinical trials (RCT). Carfilzomib-containing regimens, like KRd, can still be considered as a valid second-line option in the context of first-line daratumumab-based therapy.

HAEMATOLOGICA (2023)

Add to Collection

Article Dermatology

Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre

Julia Jeck, Sebastian M. Wingen-Heimann, Florian Jakobs, Anna Kron, Jennifer Franz, Oliver A. Cornely, Florian Kron

Summary: This study assessed the hospital costs of patients diagnosed with invasive fungal diseases (IFD) and treated with isavuconazole using real-world data. The results showed that treating IFD requires significant resources, often involves intensive care, and incurs high hospital treatment costs.

MYCOSES (2023)

Add to Collection

Letter Immunology

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021

Jens T. Van Praet, Ben Serrien, Nathalie Ausselet, Gilles Darcis, Remy Demeester, Paul De Munter, Marie-Angelique De Scheerder, Jean-Christophe Goffard, Agnes Libois, Peter Messiaen, Jean Cyr Yombi, Dominique Van Beckhoven

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2023)

Add to Collection

Article Infectious Diseases

The Argentinian landscape of mycological diagnostic capacity and treatment accessibility

Fernando Riera, Juan Pablo Caeiro, Oliver A. Cornely, Jon Salmanton-Garcia

Summary: Immunosuppressed patients, transplant recipients, and those with acute or chronic respiratory disease are at increased risk for invasive fungal infections in Argentina. Little is known about the quality of available diagnostic and treatment armamentaria for invasive fungal infections in the country, despite the national public system guaranteeing universal access to health care.

MEDICAL MYCOLOGY (2023)

Add to Collection

Article Immunology

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Alessandro Busca, Jon Salmanton-Garcia, Francesco Marchesi, Francesca Farina, Guldane Cengiz Seval, Jaap Van Doesum, Nick C. De Jonge, Nathan C. Bahr, Johan Maertens, Joseph S. Meletiadis, Nicola S. Fracchiolla, Barbora Weinbergerova, Luisa Verga, Zdenek Racil, Moraima Jimenez, Andreas Glenthoj, Ola Blennow, Alina Daniela Tanase, Martin Schoenlein, Lucia Prezioso, Nina F. Khanna, Rafael F. Duarte, Pavel Zak, Marcio Nucci, Marina Machado, Austin Kulasekararaj, Ildefonso Espigado, Elizabeth De Kort, Jose-Maria Ribera-Santa Susana, Monia Marchetti, Gabriele Magliano, Iker Falces-Romero, Osman Ilhan, Emanuele Ammatuna, Sofia Zompi, Panagiotis Tsirigotis, Anastasia Antoniadou, Giovanni Paolo Maria Zambrotta, Anna Nordlander, Linda Katharina Karlsson, Michaela Hanakova, Giulia Dragonetti, Alba Cabirta, Caroline Berg Venemyr, Stefanie Graefe, Jens Van Praet, Athanasios Tragiannidis, Verena Petzer, Alberto Lopez-Garcia, Federico Itri, Ana Groh, Eleni Gavriilaki, Michelina Dargenio, Laman A. Rahimli, Oliver A. Cornely, Livio Pagano

Summary: This multicenter retrospective study analyzed the outcome and risk factors for mortality in 326 adult HSCT patients who developed COVID-19. The results showed that age, comorbidities, active hematologic disease, timing from transplant, and severity of the infection were associated with a higher risk of mortality. The overall mortality rate was 21%, with COVID-19 being the main or secondary cause of death in 16% of the patients.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Jon Salmanton-Garcia, Francesco Marchesi, Maria Gomes da Silva, Francesca Farina, Julio Davila-Valls, Yavuz M. Bilgin, Andreas Glenthoj, Iker Falces-Romero, Jaap Van Doesum, Jorge Labrador, Caterina Buquicchio, Shaimaa El-Ashwah, Verena Petzer, Jens Van Praet, Martin Schoenlein, Michelina Dargenio, Gustavo-Adolfo Mendez, Stef Meers, Federico Itri, Antonio Giordano, Laszlo Imre Pinczes, Ildefonso Espigado, Zlate Stojanoski, Alberto Lopez-Garcia, Lucia Prezioso, Ozren Jaksic, Antonio Vena, Nicola S. Fracchiolla, Tomas Jose Gonzalez-Lopez, Natasa Colovic, Mario Delia, Barbora Weinbergerova, Monia Marchetti, Joyce Marques de Almeida, Olimpia Finizio, Caroline Besson, Monika M. Biernat, Toni Valkovic, Tobias Lahmer, Annarosa Cuccaro, Irati Ormazabal-Velez, Josip Batinic, Noemi Fernandez, Nick De Jonge, Carlo Tascini, Amalia N. Anastasopoulou, Remy Dulery, Maria Ilaria Del Principe, Gaetan Plantefeve, Mario Virgilio Papa, Marcio Nucci, Moraima Jimenez, Avinash Aujayeb, Jose-angel Hernandez-Rivas, Maria Merelli, Chiara Cattaneo, Ola Blennow, Anna Nordlander, Alba Cabirta, Gina Varricchio, Maria Vittoria Sacchi, Raul Cordoba, Elena Arellano, Stefanie K. Grafe, Dominik Wolf, Ziad Emarah, Emanuele Ammatuna, Ditte Stampe Hersby, Sonia Martin-Perez, Raquel Nunes Rodrigues, Laman Rahimli, Livio Pagano, Oliver A. Cartney

Summary: Nirmatrelvir/ritonavir treatment is associated with lower mortality in hematological malignancy patients. The treatment is related to the presence of extra-pulmonary symptoms and vaccination status for COVID-19, but not chronic pulmonary disease or obesity.

ECLINICALMEDICINE (2023)

Add to Collection

Article Hematology

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis

Sjoerd J. F. Hermans, Jurjen Versluis, Myriam Labopin, Sebastian Giebel, Yvette van Norden, Ivan Moiseev, Didier Blaise, Jose L. Diez Martin, Ellen Meijer, Montserrat Rovira, Goda Choi, Anna Maria Raiola, Yener Koc, Peter Remenyi, Jan Vydra, Nicolaus Kroeger, Simona Sica, Massimo Martino, Gwendolyn van Gorkom, Patrice Chevallier, Alessandro Busca, Concepcion Herrera Arroyo, Eolia Brissot, Zinaida Peric, Arnon Nagler, Roni Shouval, Fabio Ciceri, Jan J. Cornelissen, Mohamad Mohty

Summary: PTCY-based GVHD prophylaxis reduces the incidence of GVHD and nonrelapse mortality after alloSCT. We developed a novel PTCY-specific NRM-risk model that better predicts 2-year NRM compared to existing models.

HEMASPHERE (2023)

Add to Collection

Article Infectious Diseases

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis

Julia Jeck, Florian Jakobs, Melina S. Kurte, Oliver A. Cornely, Florian Kron

Summary: This study conducts a cost-of-illness analysis of Candida infections, finding that the treatment of candidiasis is costly and reducing ICU length of stay can lead to significant cost savings.

JAC-ANTIMICROBIAL RESISTANCE (2023)

Add to Collection

Article Mycology

Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study

Matthias Egger, Jon Salmanton-Garcia, Aleksandra Barac, Jean-Pierre Gangneux, Helene Guegan, Valentina Arsic-Arsenijevic, Tadeja Matos, Rok Tomazin, Nikolai Klimko, Matteo Bassetti, Helena Hammarstroem, Eelco F. J. Meijer, Jacques F. Meis, Juergen Prattes, Robert Krause, Oguz Resat Sipahi, Ulrike Scharmann, P. Lewis White, Guillaume Desoubeaux, Julio Garcia-Rodriguez, Carolina Garcia-Vidal, Sonia Martin-Perez, Maite Ruiz, Mario Tumbarello, Alida Fe Talento, Benedict Rogers, Katrien Lagrou, Jens van Praet, Sevtap Arikan-Akdagli, Maiken C. Arendrup, Philipp Koehler, Oliver A. Cornely, Martin Hoenigl

Summary: This sub-analysis of the Candida III study investigated the demographical and clinical characteristics of patients with candidemia who required prolonged hospitalization for completion of intravenous antifungal treatment. The study found that the use of initial echinocandin treatment was associated with prolonged hospital stay, while factors such as neutropenia, intensive care unit admission, catheter related candidemia, total parenteral nutrition, and C. parapsilosis infection were associated with shorter hospitalization.

MYCOPATHOLOGIA (2023)

Add to Collection

Article Hematology

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Monia Marchetti, Jon Salmanton-Garcia, Shaimaa El-Ashwah, Luisa Verga, Federico Itri, Zdenek Racil, Julio Davila-Valls, Sonia Martin-Perez, Jaap Van Doesum, Francesco Passamonti, Ghaith Abu-Zeinah, Francesca Farina, Alberto Lopez-Garcia, Giulia Dragonetti, Chiara Cattaneo, Maria Gomes Da Silva, Yavuz M. Bilgin, Pavel Zak, Verena Petzer, Andreas Glenthoj, Ildefonso Espigado, Caterina Buquicchio, Valentina Bonuomo, Lucia Prezioso, Stef Meers, Rafael Duarte, Rui Bergantim, Ozren Jaksic, Natasha Colovic, Ola Blennow, Martin Cernan, Martin Schoenlein, Michail Samarkos, Maria Enza Mitra, Gabriele Magliano, Johan Maertens, Marie-Pierre Ledoux, Moraima Jimenez, Fatih Demirkan, Graham P. Collins, Alba Cabirta, Stefanie K. Graefe, Anna Nordlander, Dominik Wolf, Elena Arellano, Raul Cordoba, Michaela Hanakova, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Giulia Limberti, Francesco Marchesi, Oliver A. Cornely, Livio Pagano

Summary: This study aimed to assess the effect of immunosuppressive agents on the clinical outcomes of MPN patients with COVID-19. The results showed that MPN patients receiving immunosuppressive therapies had poorer clinical outcomes and an increased risk of death.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.